| P50 | author | Michael Hust | Q38323619 |
| P2093 | author name string | Thomas Schirrmann | |
| | André Frenzel | |
| P2860 | cites work | Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use | Q68961559 |
| | The effect of compound 48/80 and of electrical field stimulation on mast cells in the isolated mouse stomach | Q69032672 |
| | Single-chain antigen-binding proteins | Q70406917 |
| | OKT3 antibody response study (OARS): a multicenter comparative study | Q70573098 |
| | Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses | Q71739934 |
| | Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung | Q72079143 |
| | Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity | Q73400866 |
| | Angiogenesis: a dynamic balance of stimulators and inhibitors | Q73447621 |
| | Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 |
| | Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab | Q74492843 |
| | Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity | Q77296337 |
| | Vascular endothelial growth factor: molecular and biological aspects | Q77808279 |
| | Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients | Q80034808 |
| | Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects | Q82732869 |
| | A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies | Q82847250 |
| | Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice | Q87656009 |
| | Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor | Q21245394 |
| | BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 |
| | Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers | Q24291148 |
| | Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 |
| | Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family | Q24303496 |
| | The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 |
| | Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants | Q24531953 |
| | VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 |
| | A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 |
| | Assembly of combinatorial antibody libraries on phage surfaces: the gene III site | Q24562659 |
| | Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 |
| | Raxibacumab | Q24644111 |
| | HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo | Q24650617 |
| | Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 | Q24675216 |
| | Anthrax lethal and edema toxins in anthrax pathogenesis | Q26852034 |
| | Drugs derived from phage display: from candidate identification to clinical practice | Q27007101 |
| | Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen | Q27620162 |
| | Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 | Q27649718 |
| | Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8 | Q27649857 |
| | A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma | Q34433792 |
| | IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma | Q34440364 |
| | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library | Q34488183 |
| | Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta | Q34514715 |
| | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 |
| | Vascular endothelial growth factor: basic science and clinical progress | Q34549887 |
| | Discovery of diverse and functional antibodies from large human repertoire antibody libraries. | Q34604961 |
| | Development trends for human monoclonal antibody therapeutics | Q34623105 |
| | Production of human monoclonal and polyclonal antibodies in TransChromo animals | Q34634571 |
| | A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties | Q34660961 |
| | High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. | Q34784806 |
| | Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway | Q34939962 |
| | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 |
| | The influence of antibody fragment format on phage display based affinity maturation of IgG. | Q35050036 |
| | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. | Q35168642 |
| | Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes | Q35498810 |
| | Management of acute attacks of hereditary angioedema: role of ecallantide | Q35508116 |
| | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 |
| | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | Q35605418 |
| | Generation and analysis of the improved human HAL9/10 antibody phage display libraries | Q35608279 |
| | Cytokine disturbances in systemic lupus erythematosus | Q35617573 |
| | Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis | Q35637322 |
| | Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis | Q35639941 |
| | Structural differences of amyloid-β fibrils revealed by antibodies from phage display | Q35666604 |
| | The discovery and development of belimumab: the anti-BLyS-lupus connection | Q35691272 |
| | Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B | Q35779652 |
| | Necitumumab: First Global Approval | Q35884714 |
| | Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. | Q35971552 |
| | Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. | Q36023082 |
| | Immunogenicity of engineered antibodies | Q36105046 |
| | The ErbB receptors and their ligands in cancer: an overview. | Q36108987 |
| | Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E | Q36126718 |
| | Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study | Q36215839 |
| | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma | Q40197990 |
| | A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. | Q40280501 |
| | Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin | Q40316237 |
| | Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis | Q40410287 |
| | Production of fully human antibodies by transgenic mice | Q40425294 |
| | CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study | Q40678725 |
| | The tumor necrosis factor ligand and receptor families. | Q40990575 |
| | Assembly of a functional immunoglobulin Fv fragment in Escherichia coli | Q41278018 |
| | Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes | Q41630608 |
| | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial | Q41692347 |
| | Antibodies to watch in 2014. | Q42461882 |
| | Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study | Q42603607 |
| | Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. | Q42944465 |
| | Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice | Q43053667 |
| | Which are the antibodies to watch in 2013? | Q43175696 |
| | Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody | Q43803820 |
| | 5 Humanization of monoclonal antibodies | Q44038659 |
| | Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis | Q44064388 |
| | Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders | Q44150789 |
| | Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions | Q44182322 |
| | Camelid immunoglobulins and nanobody technology. | Q47221693 |
| | BAFF augments certain Th1-associated inflammatory responses. | Q47810975 |
| | High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice | Q47960649 |
| | Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. | Q51538182 |
| | A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. | Q51700126 |
| | Systemic lupus erythematosus. | Q51834159 |
| | Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. | Q51918489 |
| | Construction and characterization of functional anti-epiregulin humanized monoclonal antibodies. | Q53670359 |
| | Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. | Q53787487 |
| | Ecallantide. | Q55052637 |
| | Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery | Q56031831 |
| | Construction of human antibody gene libraries and selection of antibodies by phage display | Q56891541 |
| | Handbook of Therapeutic Antibodies | Q58008006 |
| | Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression | Q63548690 |
| | Isolation of high affinity human antibodies directly from large synthetic repertoires. | Q34331136 |
| | A phase 1 study investigating DX-2930 in healthy subjects | Q34427152 |
| | Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma | Q34429203 |
| | Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors | Q36389203 |
| | Antibody-selectable filamentous fd phage vectors: affinity purification of target genes | Q36434701 |
| | Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery | Q36544167 |
| | Engineering of therapeutic antibodies to minimize immunogenicity and optimize function | Q36564145 |
| | The epidermal growth factor receptor pathway: a model for targeted therapy | Q36603677 |
| | Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. | Q36633120 |
| | Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease | Q36677345 |
| | Recombinant therapeutic antibodies | Q36709031 |
| | Vascular endothelial growth factor (VEGF) signaling in tumor progression | Q36745878 |
| | Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer | Q36750569 |
| | Biological characterization of human monoclonal antibodies to rabies virus | Q36808624 |
| | Antibodies to watch in 2016. | Q37138505 |
| | Colony-stimulating factors in inflammation and autoimmunity. | Q37190439 |
| | Interaction of antibodies with ErbB receptor extracellular regions | Q37320814 |
| | A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 |
| | The role of IL-23/IL-17 axis in lupus nephritis | Q37397437 |
| | Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy | Q37597158 |
| | An improved manufacturing process for Xyntha/ReFacto AF. | Q37664900 |
| | Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. | Q37698936 |
| | The therapeutic potential of TRAIL receptor signalling in cancer cells. | Q37962655 |
| | The role of vaccination in rabies prevention | Q38002621 |
| | Bortezomib combination therapy in multiple myeloma | Q38021041 |
| | Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. | Q38166329 |
| | Raxibacumab: potential role in the treatment of inhalational anthrax | Q38210540 |
| | The efficacy of novel B cell biologics as the future of SLE treatment: a review | Q38242432 |
| | The therapeutic monoclonal antibody market | Q38296275 |
| | The prevention and management of rabies | Q38318583 |
| | Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer | Q38332364 |
| | Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. | Q38433102 |
| | Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study | Q38453674 |
| | The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. | Q39828671 |
| | Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer | Q40126331 |
| | Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody | Q27684478 |
| | VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface | Q27765383 |
| | Identification of a new endothelial cell growth factor receptor tyrosine kinase | Q28117368 |
| | BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 |
| | Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator | Q28183674 |
| | Domain antibodies: proteins for therapy | Q28211838 |
| | Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition | Q28238040 |
| | Antibodies to watch in 2015 | Q28253501 |
| | Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels | Q28301776 |
| | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 |
| | Antibodies for biodefense | Q28394941 |
| | Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo | Q28483998 |
| | Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 | Q28570936 |
| | Rise and fall of an anti-MUC1 specific antibody | Q28743508 |
| | Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus | Q28752041 |
| | Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 |
| | Anthrax as a biological weapon, 2002: updated recommendations for management | Q29615587 |
| | Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface | Q29616401 |
| | Angiogenic factors | Q29620582 |
| | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 |
| | A helper phage to improve single-chain antibody presentation in phage display | Q30641776 |
| | New series of vectors for phage display and prokaryotic expression of proteins. | Q30664759 |
| | A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies | Q30717070 |
| | Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy | Q30790872 |
| | On the influence of vector design on antibody phage display | Q30826435 |
| | Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides | Q30836158 |
| | The production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease | Q30865607 |
| | Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries | Q30898148 |
| | Antibody arrays for high-throughput screening of antibody-antigen interactions | Q30918339 |
| | Recombinant Antibodies to the Small GTPase Rab6 as Conformation Sensors | Q30927533 |
| | Identification of scFv antibody fragments that specifically recognise the heroin metabolite 6-monoacetylmorphine but not morphine | Q30981656 |
| | FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines | Q30984508 |
| | Single domain camel antibodies: current status. | Q31005004 |
| | Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries | Q31092626 |
| | Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity | Q31153818 |
| | Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. | Q32038879 |
| | Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library | Q32060783 |
| | From rodent reagents to human therapeutics using antibody guided selection | Q33214330 |
| | The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries | Q33217631 |
| | Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. | Q33226862 |
| | Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. | Q33242744 |
| | A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration | Q33251763 |
| | High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation | Q33285349 |
| | Application of phage display to high throughput antibody generation and characterization | Q33307783 |
| | In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification | Q33362679 |
| | First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity | Q33370751 |
| | Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens | Q33381463 |
| | Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. | Q33385878 |
| | Making antibody fragments using phage display libraries | Q33392386 |
| | Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 |
| | A surface expression vector for antibody screening | Q33402114 |
| | Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire | Q33513799 |
| | Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. | Q33526822 |
| | Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening | Q33566182 |
| | Human-like antibodies neutralizing Western equine encephalitis virus | Q33573599 |
| | Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo | Q33588683 |
| | Generating recombinant antibodies to the complete human proteome | Q33600779 |
| | Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer | Q33658593 |
| | A human scFv antibody generation pipeline for proteome research | Q33706675 |
| | Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. | Q33710574 |
| | Beyond natural antibodies: the power of in vitro display technologies | Q33841864 |
| | Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus | Q33928629 |
| | Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 |
| | HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems | Q33998323 |
| | Phage antibodies: filamentous phage displaying antibody variable domains | Q34031345 |
| | Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study | Q34187345 |
| | Human antibodies from transgenic mice | Q34289925 |
| | Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis | Q34317197 |
| | Making antibodies by phage display technology | Q34328794 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 7 | |
| P921 | main subject | antibody | Q79460 |
| | globulins | Q321710 |
| | monoclonal antibody | Q422248 |
| | blood proteins | Q425056 |
| | phage display | Q896217 |
| | biomedical investigative technique | Q66648976 |
| P304 | page(s) | 1177-1194 | |
| P577 | publication date | 2016-07-14 | |
| | 2016-10-01 | |
| P1433 | published in | Monoclonal Antibodies | Q6714645 |
| P1476 | title | Phage display-derived human antibodies in clinical development and therapy | |
| P478 | volume | 8 | |